(Q34534365)

2 August 2017

1 reference

title

Review article: Helicobacter pylori infection in peptic ulcer haemorrhage (English)

1 reference

Helicobacter pylori infectious disease

2 August 2017

0 references

1 reference

van Leerdam ME

1

1 reference

2 August 2017

Tytgat GN

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

Alimentary Pharmacology & Therapeutics

2 August 2017

published in

1 reference

2 August 2017

volume

16 Suppl 1

1 reference

2 August 2017

page(s)

66-78

1 reference

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Peptic ulcer disease is strongly associated with Helicobacter pylori in east, west, central and South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Attributable risk of H. pylori in peptic ulcer disease: does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

The Treatment ofHelicobacter pyloriInfection in the Management of Peptic Ulcer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Helicobacter pylori infection in peptic ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Helicobacter pylori in duodenal and gastric ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Cure of duodenal ulcer associated with eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Helicobacter pylori and bleeding duodenal ulcer: prevalence of the infection and role of non-steroidal anti-inflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Chemotactic activity of Helicobacter pylori sonicate for human polymorphonuclear leucocytes and monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Interactions among gastric somatostatin, interleukin-8 and mucosal inflammation in Helicobacter pylori-positive peptic ulcer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Helicobacter pylori genotypes, host factors, and gastric mucosal histopathology in peptic ulcer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Incidence and pattern of peptic ulcer bleeding in a defined geographical area. DUSUK Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

21 January 2018

Bleeding peptic ulcer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Early endoscopy in upper gastrointestinal hemorrhage: associations with recurrent bleeding, surgery, and length of hospital stay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Risk assessment after acute upper gastrointestinal haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Review article:invasive and non-invasive tests for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Search and treat strategy to eliminate Helicobacter pylori associated ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Regular review: treatment of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Helicobacter pylori: rational management options

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Antibiotic resistance in Helicobacter pylori: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

The accuracy of the Helicobacter pylori stool antigen test in diagnosing H. pylori in treated and untreated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

The effect of the eradication of Helicobacter pylori infection on hemorrhage because of duodenal ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Gastroenterological procedures among patients with disorders of hemostasis: evaluation and management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Helicobacter pylori and nonsteroidal anti-inflammatory drugs: a three-way debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Nonsteroidal anti-inflammatory drug gastropathy and Helicobacter pylori: the search for an improbable consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Patient awareness of the adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study☆, ☆☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

Ulcer Bleeding and Perforation: Non-steroidal Anti-inflammatory Drugs orHelicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.0160S1066.X

10.1046/J.1365-2036.2002.0160S1066.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference